Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Review, H2 2015 RnRMarketResearch.com Adds “Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Review, H2 2015” which provides an overview of the Secondary Progressive Multiple Sclerosis therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Secondary Progressive Multiple Sclerosis (SPMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Secondary Progressive Multiple Sclerosis (SPMS) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on H2, 2015 Pipeline Review of “Secondary Progressive Multiple Sclerosis” addition with 26 market data tables and 13 figures, spread across 98 pages is http://www.rnrmarketresearch.com/secondary-progressive-multiple-sclerosis-spmspipeline-review-h2-2015-market-report.html . This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from our proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources, put together by our professional's team. Drug profiles/records featured in the report undergoes periodic updating following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Companies Discussed/Mentioned in this Research: AB Science SA, Biogen, Inc., Daval International Limited, Genzyme Corporation, Glialogix, Inc., Immune Response BioPharma, Inc., Innate Immunotherapeutics Limited, Kyorin Pharmaceutical Co., Ltd., MedDay, Merck KGaA, Novartis AG and Opexa Therapeutics, Inc.
Drugs Profile Discussed in this Research: Aimspro, ApE, ATXMS-1467, biotin, DC-TAB, GLX-1112, GZ-402668, ibudilast, imilecleucel-t, interferon beta-1b, IR-902, masitinib, MIS-416, natalizumab, opicinumab, OSX-110 and siponimod Inquire before buying for this report http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=414333 . (This is a premium report price at US$2000 for a single user PDF license)
Scope: •
The report provides a snapshot of the global therapeutic landscape of Secondary Progressive Multiple Sclerosis (SPMS)
•
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
•
The report reviews key players involved in the therapeutics development for Secondary Progressive Multiple Sclerosis (SPMS) and enlists all their major and minor projects
•
The report summarizes all the dormant and discontinued pipeline projects
•
A review of the Secondary Progressive Multiple Sclerosis (SPMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
•
Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
•
A detailed assessment of monotherapy and combination therapy pipeline projects
•
Coverage of the Secondary Progressive Multiple Sclerosis (SPMS) pipeline on the basis of target, MoA, route of administration and molecule type
•
Latest news and deals relating related to pipeline products
Reasons to buy: •
Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
•
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
•
Develop strategic initiatives by understanding the focus areas of leading companies
•
Identify and understand important and diverse types of therapeutics under development for Secondary Progressive Multiple Sclerosis (SPMS)
•
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
•
Devise corrective measures for pipeline projects by understanding Secondary Progressive Multiple Sclerosis (SPMS) pipeline depth and focus of Indication therapeutics
•
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
•
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Explore More Research Report on Multiple Sclerosis Drugs Market. Multiple sclerosis is a type of auto immune disorder which is caused due to significant damage to the myelin sheath. Owing to the damage, the speed of nerve response is slowed down and thus the reaction to the stimuli and the nerve signal speed would be significantly reduced. There are a lot of different symptoms that can be used for the sake of determining if a patient is suffering from this disorder. There are a lot of multiple sclerosis drugs that can be found. Although, these drugs are not capable of curing patients, they can delay the trouble. There are various other medicines as well and the main working strategy is by reducing muscle spasms and delaying the damage in the nerves. Most of the auto immune disorders cannot be cured permanently and the different drugs only serve to delay the inevitable. Thus, by using the multiple sclerosis drugs, these patients can prolong the longevity of their life as the rate of deterioration of myelin sheath will be reduced and thus the nerve pain would be lessened as well.
About Us: RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.